Skip to main content Skip to main navigation menu Skip to site footer

Association between immunoscore with lymphovascular invasion and clinical staging in colorectal cancer

  • Raden Achmad Hussein Fachruddin ,
  • Wifanto Saditya Jeo ,


Background: Despite the immunoscore benefit function as a prognostic tool in colorectal cancer, no study reports its reason. This study tried to identify the relationship between the immunoscore and the incidence of lymphovascular invasion and clinical stage in colorectal cancer patients as a mechanism for immunoscore to predict the outcome of colorectal cancer.

Methods: This is correlational with a cross-sectional study that analyzed medical record data and laboratory results. Immunoscore was collected from an independent private laboratory, and other data (gender, age, diagnosis, tumor location, lymphovascular invasion) were from medical records from the Private Hospital colorectal cancers registry. Data collection was carried out from October to December 2022. We performed data analysis with the Chi-Square statistical test with a significant p-value<0.05.

Results: The results showed that the majority of subjects had tumor locations in the rectosigmoid (25%) and advanced stages (65%) with lymphovascular invasion findings (80%). Chi-Square statistical test shows the result of p = 0.025 and p = 0.64, respectively, lymphovascular invasion and clinical staging.

Conclusion: This study shows that the immunoscore has a dependent relationship with the incidence of lymphovascular invasion and an independent relationship with the clinical stage of TNM in colorectal cancer patients. The application and use of immunoscore are beneficial for clinicians to give suggestions and understanding to patients about their choice of therapy also outcome for the patient.


  1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre L, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Cancer J Clin. 2020;70(4):394–424.
  2. Rawla P, Sunkara T, Barsouk A. Epidemiology of colorectal cancer: incidence, mortality, survival, and risk factors. Gastroenterology Review/Przegląd Gastroenterologiczny. 2019;14(2):89-103.
  3. Dekker E, Tanis PJ, Vleugels JLA, Kasi PM, Wallace MB. Colorectal cancer. Lancet. 2019;394(10207):1467-1480.
  4. Bianchi G, Annicchiarico A, Morini A, Pagliai L, Crafa P, Leonardi F, et al. Three distinct outcomes in patients with colorectal adenocarcinoma and lymphovascular invasion: the good, the bad, and the ugly. Int J Colorectal Dis. 2021;36(12):2671-2681.
  5. Schmitt M, Greten FR. The inflammatory pathogenesis of colorectal cancer. Nat Rev Immunol. 2021;21(10):653-667.
  6. Angell HK, Bruni D, Barrett JC, Herbst R, Galon J. The immunoscore: Colon cancer and beyond. Clin Cancer Res. 2020;26(2):332–339.
  7. Mlecnik B, Tosolini M, Kirilovsky A. Histopathologic-based prognostic factors of colorectal cancers are associated with the state of the local immune reaction. J Clin Oncol Off J Am Soc Clin Oncol. 2011;29(6):610–618.
  8. Koch M, Beckhove P, op den Winkel J, Autenrieth D, Wagner P, Nummer D, et al. Tumor Infiltrating T Lymphocytes in Colorectal Cancer. Ann Surg. 2006;244(6):986-993.
  9. Malka D, Lièvre A, André T, Taïeb J, Ducreux M, Bibeau F. Immune scores in colorectal cancer: Where are we?. Eur J Cancer. 2020;140:105-118.
  10. Schmitt M, Greten FR. The inflammatory pathogenesis of colorectal cancer. Nat Rev Immunol. 2021;21(10):653-667.
  11. Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pagès C, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science. 2006;313(5795):1960–1964.
  12. Jass JR. Lymphocytic infiltration and survival in rectal cancer. J Clin Pathol. 1986;39(6):585–589.
  13. Gao P, Song Y-xi, Wang Z-ning, Xu Y-ying, Tong L-lin, Sun J-xu, et al. Is the prediction of prognosis not improved by the seventh edition of the TNM classification for colorectal cancer? analysis of the surveillance, epidemiology, and end results (SEER) database. BMC Cancer. 2013;13(1):1-6.
  14. Hanahan D, Weinberg RA. Hallmarks of cancer: The next generation. Cell. 2011;144(5):646–674.
  15. Trabelsi M, Farah F, Zouari B, Jaafoura MH, Kharrat M. An Immunoscore System Based On CD3+ And CD8+ Infiltrating Lymphocytes Densities To Predict The Outcome Of Patients With Colorectal Adenocarcinoma. Onco Targets Ther. 2019;12(1):8663–8673.
  16. Pagès F, Berger A, Camus M, Sanchez-Cabo F, Costes A, Molidor R, et al. Effector memory T cells, early metastasis, and survival in colorectal cancer. N Engl J Med. 2005;353(25):2654–2666.
  17. Pagès F, Mlecnik B, Marliot F. International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study. Lancet. 2018;391(10135):2128–2139.
  18. Mlecnik B, Bifulco C, Bindea G, Marliot F, Lugli A, Lee JJ, et al. Multicenter International Society for Immunotherapy of Cancer Study of the consensus Immunoscore for the prediction of survival and response to chemotherapy in stage III colon cancer. J Clin Oncol. 2020;38(31):3638–3651.
  19. Zhong JW, Yang SX, Chen RP, Zhou YH, Ye MS, Miao L, et al. Prognostic value of lymphovascular invasion in patients with stage III colorectal cancer: A retrospective study. Med Sci Monit. 2019;25:6043–6050.
  20. Jiang HH, Zhang ZY, Wang XY, Tang X, Liu HL, Wang AL, et al. Prognostic significance of lymphovascular invasion in colorectal cancer and its association with genomic alterations. World J Gastroenterol. 2019;25(20):2489–2502.
  21. Church D, Sansom O, Maka N, Edwards J, Oien K, Iveson T, et al. Clinical performance of immunoscore in stage III colorectal cancer patients in the SCOT and IDEA-HORG cohorts. Am J Clin Oncol. 2022;40(4):196
  22. Jorissen RN, Sakthianandeswaren A, Sieber OM. Immunoscore-has it scored for colon cancer precision medicine? Ann Transl Med. 2018;6(1):S23.
  23. Sudoyo WA, Kurniawan AN, Kusumo GD, Kusumo K, Rexana FA, Yunus M, et al. Increased CD8 tumor infiltrating lymphocytes in colorectal cancer microenvironment supports an adaptive immune resistance mechanism of PD-L1 expression. Asian Pac J Cancer Prev. 2019; 20(11):3421-3427.
  24. Pagès F, André T, Taieb J, Vernerey D, Henriques J, Borg C, et al. Prognostic and predictive value of the Immunoscore in stage III colon cancer  patients treated with oxaliplatin in the prospective idea France Prodige-GERCOR Cohort Study. Ann Oncol. 2020;31(7):921–929.
  25. Sinicrope FA, Shi Q, Hermitte F, Zemla TJ, Mlecnik B, Benson AB, et al. Contribution of immunoscore and molecular features to survival prediction in stage III colon cancer. JNCI Cancer Spectr. 2020;4(3):pkaa023.
  26. Marliot F, Chen X, Kirilovsky A, Sbarrato T, El Sissy C, Batista L, et al. Analytical validation of the Immunoscore and its associated prognostic value in patients with colon cancer. J Immunother Cancer. 2020;8(1):e000272.
  27. Wiranata S, Anjani IAW, Saputra IPGS, Sadvika IGAS, Prabawa IPY, Supadmanaba IG,et al. Pretreatment neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio as a stage determination in breast cancer. Open Access Macedonian Journal of Medical Sciences. 2020;8(B):1058-1063.
  28. Luther Y, Warsinggih Hamid F, Uwuratuw JA, Syarifuddin E, Prihantono. The association of age, gender, tumor site, and smoking habit with histopathologic types of colorectal carcinoma patients in Wahidin Sudirohusodo Hospital, Makassar, Indonesia. Indonesia Journal of Biomedical Science. 2022;16(2):60–64.
  29. Wibowo AA, Sitompul A, Alfi Y, Oktaviyanti IK, Lahdimawan A, Damayanthi ED. An increase in inflammatory cells related to the increase incidence of colitis and colorectal cancer. Bali Medical Journal. 2022;11(1):499–502.

How to Cite

Fachruddin, R. A. H., & Jeo, W. S. (2023). Association between immunoscore with lymphovascular invasion and clinical staging in colorectal cancer. Bali Medical Journal, 12(1), 1089–1093.




Search Panel

Raden Achmad Hussein Fachruddin
Google Scholar
BMJ Journal

Wifanto Saditya Jeo
Google Scholar
BMJ Journal